Role of miR-101a in targeting Cox-2 to attenuate chondrocyte hypertrophic differentiation and osteoarthritis progression
MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression post-transcriptionally, often playing critical roles in various biological processes. Recent studies have highlighted the involvement of miRNAs in chondrogenesis by targeting key marker genes. Among these, miR-101a has been identified as a significant regulator, previously reported to target cyclooxygenase-2 (Cox-2, ptgs2) in various contexts. Here, we investigate the role of miR-101a in chondrocyte hypertrophy and osteoarthritis (OA) progression, focusing on its regulation of Col10a1 expression. Using multiple web-based tools (TargetScan, PicTar, miRDB, and miRCODE), we identified miR-101a as a potential regulator of Col10a1. Our <i>in vitro</i> experiments demonstrated that miR-101a was down-regulated during chondrocyte hypertrophy in MCT and ATDC5 cells, while Col10a1 and Cox-2 expression levels were up-regulated. Overexpression of miR-101a via mimics resulted in a significant decrease in Col10a1 and Cox-2 at both mRNA and protein levels, whereas inhibition of miR-101a led to their up-regulation. Additionally, MMP-13 protein levels were reduced upon miR-101a overexpression, with no significant changes in Sox9 and Runx2 expression. Luciferase reporter assays confirmed that Cox-2 was a direct target of miR-101a, suggesting that miR-101a indirectly regulates Col10a1 expression via Cox-2. <i>In vivo</i>, intra-articular injection of miR-101a mimics in a medial meniscus-induced OA mouse model resulted in decreased Col10a1 expression and reduced articular damage, supporting the protective role of miR-101a in OA progression. Our findings highlight miR-101a as a negative regulator of chondrocyte hypertrophy through Cox-2, and could be a potential target for further exploration in OA therapy.
Authors
- Rui Mi (ORCID: https://orcid.org/0000-0002-3182-135X)
- Tianxiang Zhu (ORCID: https://orcid.org/0000-0002-2398-0510)
- Huiqin Bian
- Longwei Qiao (ORCID: https://orcid.org/0000-0002-5264-9886)
- Biaohua Chen (ORCID: https://orcid.org/0000-0002-9871-9560)
- Tiaotiao Han
- Qiping Zheng
- Ran Deng (ORCID: https://orcid.org/0000-0001-9540-9703)
- Qian Wang (ORCID: https://orcid.org/0000-0002-2149-384X)
- Wei Rong (ORCID: https://orcid.org/0000-0002-7897-576X)
- Yaojuan Lu
- Yuting Liang (ORCID: https://orcid.org/0000-0001-5443-4486)
Institutions
- Jiangsu University (CN)
- Soochow University (CN)
- Shenzhen Bioeasy Biotechnology (China) (CN)
- University of Chicago Medical Center (US)
- Jiangsu University of Science and Technology (CN)
- Wuxi Ninth People's Hospital (CN)
- Shenzhen Institute for Drug Control (CN)
- First Affiliated Hospital of Soochow University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Genes & Diseases
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1016/j.gendis.2025.101839
- Primary Topic
- Osteoarthritis Treatment and Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Jiangsu Provincial Key Research and Development Program
- Social Science Foundation of Jiangsu Province